2 active not recruiting, 2 completed, 2 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Completed 2, Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow danvatirsen: new trials by email Literature Review of danvatirsen trials Research Report on danvatirsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC Danvatirsen, Pembrolizumab - HNSCC | Phase 2 | Terminated | Flamingo Therapeutics NV | 69 | 2023-05-30 | 2026-01-30 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage | Phase 2 | Completed | MedImmune LLC | 84 | 2019-03-08 | 2022-02-24 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 528 | 2017-12-18 | 2025-10-27 |
| Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-03-02 | 2025-05-06 |
| Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck AZD9150, MEDI4736, AZD5069 - Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 1 / Phase 2 | Completed | AstraZeneca | 340 | 2015-08-06 | 2026-02-11 |
| AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites AZD9150 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2015-04-03 | 2017-05-15 |
Carcinoma, Non-Small-Cell Lung (3) · Ascites (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Turcot syndrome (1)
AstraZeneca (2) · Flamingo Therapeutics NV (1) · M.D. Anderson Cancer Center (1) · MedImmune LLC (1) · National Cancer Institute (NCI) (1)
United States (6) · Spain (3) · Canada (2) · France (2) · Germany (2) · Italy (2) · South Korea (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Israel (1) · Portugal (1) · Switzerland (1)
David S Hong (1) · Dr David Hong, MD (1) · John Heymach, M.D, Ph.D (1) · Nabil Saba, MD (1) · Tim F Greten, M.D. (1)
PMID 37707791, PMID 38351187, PMID 39886125
2015 (1), 2017 (1), 2023 (1)